GC
ARQT icon

Guggenheim Capital’s Arcutis Biotherapeutics ARQT Stock Holding History

Guggenheim Capital’s Portfolio ARQT Stock Details ARQT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.02M Buy
43,234
+10,722
+33% +$274K 0.01% 989
2025
Q4 		$944K Buy
+32,512
New +$832K 0.01% 983
2023
Q2 		– Sell
-10,531
Closed -$116K – 1869
2023
Q1 		$116K Buy
10,531
+234
+2% +$3.38K ﹤0.01% 1868
2022
Q4 		$152K Sell
10,297
-1,598
-13% -$27.9K ﹤0.01% 1840
2022
Q3 		$228K Sell
11,895
-121
-1% -$2.74K ﹤0.01% 1750
2022
Q2 		$256K Sell
12,016
-250
-2% -$5.13K ﹤0.01% 1847
2022
Q1 		$236K Buy
12,266
+1,544
+14% +$26.1K ﹤0.01% 1980
2021
Q4 		$222K Buy
+10,722
New +$213K ﹤0.01% 1997

Other funds holding ARQT

SCM
Suvretta Capital Management New York $3.69B AUM 86.67% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $8.16B AUM 68.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $22.9B AUM 115.26% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return